Genetic Diagnosis of Hereditary Hemorrhagic Telangiectasia: Four Novel Pathogenic Variations in Turkish Patients

Mehmet Baysal1, Selma Demir2, Elif G. Ümit1, Hakan Gürkan2, Volkan Baş1, Sedanur Karaman Gülsaran1, Ufuk Demirci2, Hakkı Onur Kırkızlăr1, Ahmet Muzaffer Demir1

1Department of Hematology, Trakya University School of Medicine, Edirne, Turkey
2Department of Medical Genetics, Trakya University School of Medicine, Edirne, Turkey

Aims: Hereditary hemorrhagic telangiectasia is an autosomal dominant disorder characterized by telangiectasia, epistaxis, and vascular malformations. Pathogenic mutations were found in ENG, ACVRL1, SMAD4, and GDF genes. In this study, we present our database of patients with hereditary hemorrhagic telangiectasia regarding the phenotype-genotype relations and discuss two novel ENG gene pathogenic variations in two unrelated families.

Methods: Next Generation Sequencing analysis was performed on the peripheral blood of nine patients with hereditary hemorrhagic telangiectasia in four unrelated families. All patients were diagnosed with hereditary hemorrhagic telangiectasia according to the Curaçao criteria. Data on treatment and screenings of visceral involvement were recorded from files.

Results: We have found a pathogenic variation in either the ENG or ACVRL1 gene in each family. Two novel pathogenic variations in the ENG gene, including NM_000118.3(ENG): c.416delC (p.P139fs*24) and NM_000118.3(ENG): c.1139dupT (p.Leu380PhefsTer16), were found in the same family. The NM_000020.2(ACVRL1): c.1298C>T (p.Pro433Leu) pathogenic variation in the ACVRL1 gene in our first family and a novel heterozygous likely pathogenic NM_000020.2(ACVRL1): c.95T>C (p.Val32Ala) variation was found in our second family. Seven of the nine patients were treated with thalidomide for controlling bleeding episodes. All patients responded to thalidomide. In one patient, the response to thalidomide was lost and switched to bevacizumab.

Conclusion: In hereditary hemorrhagic telangiectasia, certain types of mutations correlate with disease phenotypes and with next generation sequencing methods. New pathogenic variations can be revealed, which might help manage patients with hereditary hemorrhagic telangiectasia.

Keywords: ENG mutations, genotype, hereditary hemorrhagic telangiectasia, phenotype

Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Rendu-Weber syndrome, is an autosomal dominant disorder with a prevalence of 1/10,000, characterized by angiodysplastic lesions. Expression of the disease is widely variable with an age-related penetrance (1). The diagnosis of hereditary hemorrhagic telangiectasia is made with the Curaçao criteria, which consist of epistaxis, telangiectasia, vascular malformations, and autosomal dominant penetrance. Three criteria are required for the definite diagnosis of hereditary hemorrhagic telangiectasia (2). The genetic abnormalities of hereditary hemorrhagic telangiectasia are pertinent to the transforming growth factor-beta/bone morphogenetic protein signaling pathway, which is the mainstay of the regulation of various physiological processes, particularly angiogenesis (3).

The endogolin (ENG), activin receptor type 1 (ACVRL1), SMAD4, activin A receptor type 1 (AVCRL1), and growth differentiation factor 2 (GDF2) genes have been identified as the underlying cause of hereditary hemorrhagic telangiectasia (4). Hereditary hemorrhagic telangiectasia phenotypes are due to mutations in the coding region of the ENG and ACVRL1 genes in the majority of patients (5), whereas SMAD4 gene mutations occur in 2%-3% of patients (6). Mutations of the BMP gene are rarely reported in patients with hereditary hemorrhagic telangiectasia. Still, mutation may not be found in more than 15% of patients who are clinically diagnosed with hereditary hemorrhagic telangiectasia (7). Patients with ENG mutations are classified as HHT1, and patients with ACVRL1 mutations are classified as HHT2. To date, more than 400 distinct mutations have been reported in the ENG gene, including deletions, insertions, duplications, nonsense, and missense mutations, and 246 mutations in the ACVRL1 gene (7-9).

Here we aimed to present the preliminary results of a genetic analysis of hereditary hemorrhagic telangiectasia in our region and report two novel ENG variations observed in two unrelated families with hereditary hemorrhagic telangiectasia.
MATERIALS AND METHODS

Subjects

Four female and five male patients from 4 unrelated families diagnosed with hereditary hemorrhagic telangiectasia were included in this study. All patients were diagnosed with hereditary hemorrhagic telangiectasia according to the Curacao criteria. The data on bleeding episodes, the requirement for transfusion and iron replacement, antiangiogenic treatments, and screenings of visceral involvement were recorded from files. Ethical approval was obtained from the local ethics committee, and written informed consent was obtained from all patients (protocol no: TUTF-BAEK 2019/259 date:01.07.2019).

Genetic analysis

All individuals were subjected to genetic counseling and molecular testing. DNA was isolated from peripheral blood samples of patients by using the EasyOne DNA isolation system (Qiagen, Hilden, Germany). A custom-designed QIAseq Targeted DNA Panel (Qiagen, Hilden, Germany) was used for sequencing the entire coding region of ACVRL1, ADAM17, ENG, GDF2, PTPN14, RASA1, and SMAD4 genes. QCI analysis (Qiagen, Hilden, Germany) was used to control quality parameters, and Clinical Insight (Qiagen, Hilden, Germany) was used to determine variations. Variants were classified according to ACMG 2015 criteria (10).

RESULTS

The mean age of the patients was 59 years (29-76). All patients presented and were diagnosed with intractable epistaxis. The mutation screening results and patient demographics are summarized in Table 1. Gastrointestinal bleeding was observed in one patient (patient no: 9), and heavy menstrual bleeding was observed in one patient (patient no: 7).

Our first family has four affected individuals with hereditary hemorrhagic telangiectasia, and all of them have a novel, heterozygous, likely pathogenic NM_000020.2(ACVRL1): c.1298C>T (p.Pro433Leu) variation. Two different missense variations, NM_000020.2:c.1298C>G (p.Pro433Arg) (10) and HGVS NM_000020.2:c.1297C>T(p.Pro433Ser) have previously been reported in the literature for the same codon of the ACVRL1 gene (11). Three of the four affected members of this family were treated with thalidomide.

The second family has two affected individuals who have a novel, heterozygous, likely pathogenic NM_000020.2(ACVRL1): c.95T>C (p.Val32Ala) variation. Another missense variation; NM_000020.2:c.95T>G (p.Val32Gly), has been reported in the literature for this position on the ACVRL1 gene (12). Both patients have clinical findings, family history, telangiectasias, and epistaxis episodes. This combination of findings in these patients was treated with thalidomide.

In our third family, we have two affected individuals, and both were affected family members. A 49-year-old and a 76-year-old mother had a novel NM_00118.3(ENG):c.416delC (p.P139fs*24) variation in the ENG gene. This variation was not reported in the dbSNP or ClinVar and classified as “pathogenic” by our laboratory according to ACMG 2015 criteria (10) (PVS1, PM2, PP3). The bleeding history of the female patient (patient no: 7) consisted of heavy menstrual bleeding alone in her early years that was treated with iron replacement and recurrent severe epistaxis after age 60, which required multiple attempts of surgical and local control. The diagnosis of hereditary hemorrhagic telangiectasia was based on the presence of three of the Curacao criteria, and her hereditary hemorrhagic telangiectasia Epistaxis severity score was 7.31 (13). To control her epistaxis episodes, oral thalidomide 100 mg/day was initially started. She responded well to thalidomide for a year and reported only trivial episodes of epistaxis without the need for medical care. Her Epistaxis severity score in the first year of treatment decreased to 4.94. Hemoglobin levels were maintained above 10 g/dL. No adverse effects were observed. However, during the second year of thalidomide, epistaxis episodes became more frequent, and her Epistaxis severity score level raised to 7.19. Treatment was switched to bevacizumab. The second member of the same family, the son, reported only trivial episodes of epistaxis, which have been managed with local measures.

The proband from the fourth family has a novel NM_000118.3(ENG):c.1139dupT (p.Leu380PhefsTer16) variation in the ENG gene. This variation was not reported in the literature or databases before and was classified as “pathogenic” by our laboratory according to ACMG 2015 criteria (PVS1, PM2, PP3) (14). This patient responded to thalidomide treatment.

TABLE 1. Summary of patient demographic information and mutational analysis

| Patient no | Gender | Age | Variation | Visceral AVM | Treatment |
|------------|--------|-----|-----------|-------------|-----------|
| 1. Family-1 Female | 66 | NM_000020.2(ACVRL1): c.1298C>T(p.Pro433Leu) | Hepatic | Thalidomide |
| 2. Family-1 Male | 46 | NM_000020.2(ACVRL1): c.1298C>T(p.Pro433Leu) | None | Thalidomide |
| 3. Family-1 Male | 57 | NM_000020.2(ACVRL1): c.1298C>T(p.Pro433Leu) | None | Thalidomide |
| 4. Family-1 Female | 27 | NM_000020.2(ACVRL1): c.1298C>T(p.Pro433Leu) | Hepatic | None |
| 5. Family-2 Female | 65 | NM_000020.2(ACVRL1): c.95T>C(p.Val32Ala) | Hepatic | Thalidomide |
| 6. Family-2 Male | 64 | NM_000020.2(ACVRL1): c.95T>C(p.Val32Ala) | None | Thalidomide |
| 7. Family-3 Female | 76 | NM_000118.3(ENG): c.416delC (p.P139fs*24) | None | Bevacizumab |
| 8. Family-3 Male | 49 | NM_000118.3(ENG): c.416delC (p.P139fs*24) | None | None |
| 9. Family-4 Male | 58 | NM_000118.3(ENG): c.1139dupT (p.Leu380PhefsTer16) | GIS, pulmonary AVM | Thalidomide |

AVM: arteriovenous malformation; GIS: gastrointestinal system

Baysal et al. Four Novel ENG Pathogenic Variations in Hereditary Hemorrhagic Telangiectasia
The initial treatment of patients was local compression, cauterization, and iron supplements, all without a sustainable response. Seven of the nine patients were further treated with thalidomide 100 mg/day orally. In two patients, no systemic treatment was necessary. The treatment was well tolerated with minor side effects comprising grade one dizziness and nausea, which did not require additional medication (15). Epistaxis episodes decreased in all patients. In one patient, thalidomide was switched to bevacizumab because of clinical effectiveness. The ACVRL1 mutation was observed in six patients. As categorized according to mutation status, six patients were observed as having HHT2, while three patients were observed as having HHT1. Detailed information regarding hereditary hemorrhagic telangiectasia type and phenotype correlations are provided in Table 2.

**DISCUSSION**

In a hypothetical model of hereditary hemorrhagic telangiectasia called a “two-hit model,” it has been suggested that a germline heterozygous mutation in the hereditary hemorrhagic telangiectasia gene may be regarded as the first hit, while inflammation, vascular injury, hypoxia, and angiogenesis may be regarded as the second hit of developing hereditary hemorrhagic telangiectasia. Similar to the multi-hit hypothesis of venous thromboembolism, haploinsufficiency alone caused by mutations may not be enough for the clinical picture; the addition of other processes may explain the “intrafamilial phenotypic variability” of the disease (8,9). As the processes of the second hit may be observed with aging, we may extrapolate that age may also be an additional hit in the variability of phenotype. Supporting this notion, in a retrospective study, epistaxis has been reported as the first symptom, whereas other manifestations related to visceral organs tended to occur at more mature ages explained by the role of inflammation, vascular injury, and aging (16). In the second family of our cohort, a mother and son had the same novel pathogenic variation with different phenotypes. The younger patient had a much milder phenotype, while the older patient had severe and challenging bleeding episodes and a non-sustained response to antiangiogenic treatments.

Endoglin is a 180 kDa transmembrane glycoprotein that functions as a co-receptor for the transforming growth factor-beta receptor complex, which regulates ALK1 and SMAD signaling (4,17). Both truncating and nontruncating mutations in ENG have demonstrated to be associated with HHT1 causing the genes to behave as null alleles, defined as haploinsufficiency. As endothelial cells are depleted with endoglin due to this haploinsufficiency, all physiological processes mediated by transforming growth factor-beta become abnormal, which leads to angiodyplasia (17-19). The severity of the phenotype is reported to be different between patients who harbor the ENG mutation though no specific variant and is related to a more severe phenotype while in patients with missense mutations, a milder phenotype is reported (10,20-22). There were 507 reported variations in the ENG gene in the Hereditary Hemorrhagic Telangiectasia Mutation Database of Utah University (23). Our patients’ variation was not reported in this database.

As hereditary hemorrhagic telangiectasia is classified according to mutations of either the ENG or ACVRL1 genes, the phenotype has also been reported to vary in HHT1, and HHT2, such as pulmonary AVMs, vary more commonly in HHT1, while hepatic AVMs vary in HHT2 (20,22). In our study, we observed similar penetrance as pulmonary penetrance in patients with hereditary hemorrhagic telangiectasia and hepatic AVMs in patients with HHT2. None of our patients had cranial AVMs. In our limited analysis; we found more ACVRL1 mutated patients than ENG mutated patients. Diagnosis of hereditary hemorrhagic telangiectasia was made with clinical findings; however, different types of mutations could cause different types of diseases. Therefore, the mutational analysis provides disease classification (HHT1, HHT2, HHT4) and genotype-phenotype correlations. Thalidomide and bevacizumab are the most commonly used agents in hereditary hemorrhagic telangiectasia. Thalidomide is mainly used in multiple myeloma and bevacizumab in several cancer types (24-26). The use of both drugs relies on rational logic, but they are not curative treatment options, and there are still large gaps and unmet needs in the treatment of patients with hereditary hemorrhagic telangiectasia. In our limited number of patients with the ACVRL1 mutation, we observed a positive effect of thalidomide, which should be evaluated with further studies.

This study has two distinct, yet related messages. The first is the existence of four novel pathogenic ENG variations, which support the genetic diagnosis of hereditary hemorrhagic telangiectasia within families, and the second message is that further supportive data are needed regarding the contribution of other factors to the phenotype of hereditary hemorrhagic telangiectasia, including age and inflammation.

**Editor-in-Chief's note:** Elif G. Ümit and Hakan Gürkan are the members of the Editorial Board of Balkan Medical Journal. However, they did not take place at any stage on the editorial decision of the manuscript.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** No financial disclosure was declared by the authors.

### REFERENCES

1. Begbie ME, Wallace GMF, Shovlin CL. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century. Postgrad Med J 2003;79:18-24.
2. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;91:66-7.

3. Shovlin CL. Hereditary hemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010;24:203-19.

4. Bayrak-Toydemir P, Mao R, Lewin S, McDonald J. Hereditary hemorrhagic telangiectasia: an overview of diagnosis and management in the molecular era for clinicians. Genet Med 2004;6:175-91.

5. Olivieri C, Pagella F, Semino L, Lanzarini L, Valacca C, Pilotto A, et al. Analysis of ENG and ACVRL1 genes in 137 HHT Italian families identifies 76 different mutations (24 novel). Comparison with other European studies. J Hum Genet 2007;52:820-9.

6. Gallione C, Aylsworth AS, Beis J, Berk T, Bernhardt B, Clark RD, et al. Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome. Am J Med Genet A 2010;152:333-9.

7. Karlsson T, Cherif H. Mutations in the ENG, ACVRL1, and SMAD4 genes and clinical manifestations of hereditary haemorrhagic telangiectasia: experience from the Center for Osler's Disease, Uppsala University Hospital. Ups J Med Sci 2018;123:153-7.

8. McDonald J, Wooderchak-Donahue W, VanSant Webb C, Whitehead K, Stevenson DA, Bayrak-Toydemir P. Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Front Genet 2015;6:1.

9. Ruiz-Llorente L, Gallardo-Vara E, Rossi E, Smadja DM, Botella LM, Bernabeu C. Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia. Expert Opin Ther Targets 2017;21:933-47.

10. Bossler AD, Richards J, George C, Godmilow L, Ganguly A. Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype. Hum Mutat 2006;27:667-75.

11. Letteboer TG, Mager HJ, Snijder RJ, Lindhout D, Ploos van Amstel HK, Zanen P, et al. Genotype-phenotype relationship for localization and age distribution of telangiectases in hereditary hemorrhagic telangiectasia. Am J Med Genet A 2008;146:2733-9.

12. Hereditary Hemorrhagic Telangiectasia Mutation Database. Salt Lake City, UT: University of Utah Department of Pathology  http://www.arup.utah.edu/database/HHT. Accessed 26 May 2019.

13. Xu M, Hou Y, Sheng L, Peng J. Therapeutic effects of thalidomide in hematologic disorders: a review. Front Med 2013;7:290-300.

14. Geisthoff UW, Nguyen HL, Roth A, Seyfert U. How to manage patients with hereditary hemorrhagic telangiectasia. Br J Haematol 2015;171:443-52.